Dose ranges reflect commonly studied amounts in published research models. This is not medical advice. For research use only. Not for human consumption.
Protocol Comparison
Skin & Hair
Research dose range
Standard research range
250 - 500 mcg
Common loading-phase convention — interpolated between the low-start dose and the trial-anchored dose below, not independently sourced at this exact range.
Research focus
Melanogenesis / Dual Pigmentation
Observed window
Visible darkening 3-7 days; peak color 2-4 weeks
Administration
Daily(loading)/Weekle
Primary pathway
MC1R / MC3R / MC4R
Dose data anchored to the 1996 Dorr et al. Phase 1 trial (0.025mg/kg SC, weight-based) and community low-dose tolerance protocols. Total published human trial population is approximately 33 people. For research use only.
MANFAAT PROTOKOL
◆
Activates MC1R on melanocytes to trigger genuine melanogenesis — the same biological process UV exposure uses, without requiring the UV.
◆
Also engages MC4R in the hypothalamus, which is why this specific compound class carries a documented secondary effect on sexual arousal.
◆
Backed by real human dose-response data from 1990s Arizona research — genuine clinical grounding, though the program was small and never advanced past early trials.
SAINS
MT-2 is a synthetic analog of alpha-MSH, engineered to be more potent and longer-lasting than the natural hormone. What sets it apart from more targeted melanocortin compounds is its lack of selectivity — it activates MC1R, MC3R, and MC4R all at once, which is exactly why one compound produces tanning, appetite suppression, and arousal effects together.
MT-2's tanning mechanism is genuine melanogenesis, not surface coloring — the same pathway UV exposure uses. That's also the source of its most serious open question: multiple melanoma case reports exist in MT-2 users, and the biological plausibility of a link is real, since the compound works by driving melanocyte activity. The published trial population — around 33 people total — is too small to establish actual cancer risk, but it's also too small to rule it out.
YANG DIHARAPKAN
Visible darkening typically begins within 3-7 days, building toward peak color over 2-4 weeks of continued dosing.
CATATAN PROTOKOL
Available in 10mg. For research use only. Full documentation included with every order.
FAQ
MT-2 doesn't selectively target one receptor — it activates MC1R for pigmentation and MC4R for central arousal pathways simultaneously, which is why both effects appear from a single compound.
Nausea, particularly with the first few doses — documented at meaningful rates in published trials, though it tends to diminish with continued use.
PRODUK TERKAIT
MELANTONTAN-2 · EKSPLORASI PEPTIDE DI INDONESIA
Halaman NovaLabs ini menampilkan produk bernama Melantontan-2 dengan ukuran 10mg. Penulisan nama pada katalog perlu dibaca bersama label kemasan dan sertifikat analisis agar identitas bahan yang dimaksud dapat ditelusuri. Dalam pencarian informasi, variasi ejaan dapat muncul pada toko, artikel, atau catatan produk, sehingga kecocokan nama tidak sebaiknya diperiksa dari judul saja.
Gunakan dokumen COA NovaLabs untuk mencari laporan yang sesuai. Periksa nomor batch, nama sampel, dan tanggal laporan, lalu baca metode serta hasil pengujian. Jika nama pada dokumen berbeda dengan katalog, tanyakan penjelasan melalui kontak NovaLabs agar hubungan antara produk dan laporan dapat dipastikan.
NovaLabs mencantumkan produk ini untuk keperluan riset. Dokumen analisis harus dibaca sesuai parameter yang diuji dan tidak dapat dijadikan kesimpulan otomatis mengenai keamanan manusia. Penilaian produk dimulai dari identitas yang konsisten, spesifikasi tertulis, dan keterlacakan batch.
Halaman katalog mencantumkan ukuran 10mg. Nama pada label dan dokumen batch tetap perlu dicocokkan.
Melanotan II dikenal dalam referensi dengan istilah MT-II. Untuk produk ini, konfirmasi identitas spesifiknya melalui label dan COA.
